Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lithia Motors, Inc. operates as an automotive retailer in the United States. The company operates through three segments: Domestic, Import, and Luxury. It offers new and used vehicles; vehicle financing services; warranties, insurance contracts, and vehicle and theft protection services; and automotive repair and maintenance services, as well as sells vehicle body and parts under the Driveway and GreenCars brand names. As of February 18, 2022, the company operated through 278 stores. It also offers its products online through 300 websites. Lithia Motors, Inc. was founded in 1946 and is headquartered in Medford, Oregon.

Lithia Motors, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MEDFORD, ORE., AUG. 18, 2026 (GLOBE NEWSWIRE) -- LITHIA & DRIVEWAY (NYSE: LAD) TODAY ANNOUNCED IT HAS BEEN NAMED TO THE FORTUNE GLOBAL 500 FOR THE SECOND CONSECUTIVE YEAR, ADVANCING TO NO.

LITHIA & DRIVEWAY ADVANCES TO NUMBER 426 ON FORTUNE GLOBAL 500

KEY HIGHLIGHTS RECORD SECOND QUARTER REVENUES OF $9.8 BILLION USED RETAIL GPUS INCREASED $339, OR 20%, SEQUENTIALLY AFTERSALES GROSS PROFIT INCREASED BY 3.1% AND GROSS MARGIN WAS 59.2%, A 120-BASIS POINT INCREASE, ON A SAME-STORE BASIS ADJUSTED SG&A AS A PERCENT OF GROSS PROFIT WAS 68.6%, A 290-BASIS POINT IMPROVEMENT SEQUENTIALLY FINANCING OPERATIONS ACHIEVED RECORD INCOME OF $37 MILLION AND RECORD ORIGINATIONS OF $884 MILLION, WITH A 17.5% PENETRATION RATE SECOND QUARTER DILUTED EARNINGS PER SHARE OF $11.54, A 17% INCREASE, AND ADJUSTED DILUTED EARNINGS PER SHARE OF $10.03, A 9% INCREASE REPURCHASED $242 MILLION OF SHARES, REPRESENTING 3.7% OF OUTSTANDING SHARES IN THE QUARTER, AND 7.6% OF OUTSTANDING SHARES IN THE FIRST HALF OF 2026 ANNOUNCED A 23% INCREASE TO QUARTERLY DIVIDEND MEDFORD, ORE., JULY 29, 2026 (GLOBE NEWSWIRE) -- LITHIA & DRIVEWAY (NYSE: LAD), THE LARGEST GLOBAL AUTOMOTIVE RETAILER, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026.

LITHIA & DRIVEWAY (LAD) REPORTS SECOND QUARTER RESULTS, ACHIEVES 17% INCREASE IN DILUTED EARNINGS PER SHARE, 9% INCREASE IN ADJUSTED DILUTED EARNINGS PER SHARE, AND RAISES QUARTERLY DIVIDEND 23%

MEDFORD, ORE., JULY 14, 2026 (GLOBE NEWSWIRE) -- LITHIA & DRIVEWAY (NYSE: LAD) TODAY ANNOUNCED ITS SECOND QUARTER 2026 RESULTS WILL BE RELEASED BEFORE THE MARKET OPENS ON WEDNESDAY, JULY 29, 2026. A CONFERENCE CALL TO DISCUSS THE EARNINGS RESULTS IS SCHEDULED FOR THE SAME DAY AT 10:00 A.M. EASTERN TIME.

LITHIA & DRIVEWAY (LAD) SCHEDULES RELEASE OF SECOND QUARTER 2026 RESULTS

MEDFORD, ORE., JUNE 09, 2026 (GLOBE NEWSWIRE) -- LITHIA & DRIVEWAY (NYSE: LAD) TODAY ANNOUNCED THAT IT RANKED NO.

LITHIA & DRIVEWAY (LAD) RISES TO NUMBER 123 ON 2026 FORTUNE 500 LIST

WARSAW, POLAND  JUNE 03, 2026  JJP BIOLOGICS, ("JJPBIO" OR THE "COMPANY") A CLINICAL-STAGE, IMMUNE-FOCUSED BIOTECH THAT ENGINEERS PRECISION ANTIBODIES TO CORRECT DERAILED IMMUNE PATHWAYS THAT DRIVE AUTOIMMUNE DISEASES AND CANCER, TODAY ANNOUNCES POSITIVE INTERIM DATA FROM ITS ONGOING PHASE 1B TRIAL EVALUATING NEBAPRUBART, ALSO KNOWN AS JJP-1212, ITS INVESTIGATIONAL POTENTIAL FIRST-IN-CLASS ANTI-CD89 ANTAGONIST, IN PATIENTS DIAGNOSED WITH LINEAR IGA DISEASE (LAD), A RARE AUTOANTIBODY-MEDIATED SKIN DISEASE.

JJP BIOLOGICS ANNOUNCES POSITIVE INTERIM PHASE 1B DATA FOR NEBAPRUBART (JJP-1212), AN ANTI-CD89 ANTAGONIST, IN LINEAR IGA DISEASE (LAD)

MEDFORD, ORE., MAY 26, 2026 (GLOBE NEWSWIRE) -- LITHIA & DRIVEWAY (NYSE: LAD) ANNOUNCED TODAY AN INCREASE TO ITS SHARE REPURCHASE AUTHORIZATION OF $500 MILLION TO BRING THE CURRENT REMAINING AUTHORIZATION TO $726 MILLION.

LITHIA & DRIVEWAY (LAD) ANNOUNCES SHARE REPURCHASE AUTHORIZATION INCREASE

KEY HIGHLIGHTS RECORD FIRST QUARTER REVENUES OF $9.3 BILLION USED VEHICLE REVENUE INCREASED 4.6% ON A SAME STORE BASIS IN THE QUARTER USED RETAIL GPUS INCREASED 9%, OR $133, SEQUENTIALLY AFTERSALES REVENUE INCREASED 3.8%, GROSS PROFIT INCREASED BY 5.7% AND GROSS MARGIN WAS 58.7%, A 100-BASIS POINT INCREASE, ON A SAME-STORE BASIS DRIVEWAY FINANCE CORPORATION ACHIEVED RECORD ORIGINATIONS OF $840 MILLION, WITH AN 18.0% PENETRATION RATE AND AN AVERAGE FICO SCORE OF 750 IN THE QUARTER FIRST QUARTER DILUTED EARNINGS PER SHARE OF $4.28 AND ADJUSTED DILUTED EARNINGS PER SHARE OF $7.34 REPURCHASED $259 MILLION OF SHARES, REPRESENTING 4.0% OF OUTSTANDING SHARES IN THE QUARTER MEDFORD, ORE., APRIL 29, 2026 (GLOBE NEWSWIRE) -- LITHIA & DRIVEWAY (NYSE: LAD), THE LARGEST GLOBAL AUTOMOTIVE RETAILER, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026.

LITHIA & DRIVEWAY (LAD) REPORTS FIRST QUARTER RESULTS

MEDFORD, ORE., APRIL 09, 2026 (GLOBE NEWSWIRE) -- LITHIA & DRIVEWAY (NYSE: LAD) TODAY ANNOUNCED ITS FIRST QUARTER 2026 EARNINGS AND FULL YEAR RESULTS WILL BE RELEASED BEFORE THE MARKET OPENS ON WEDNESDAY, APRIL 29, 2026. A CONFERENCE CALL TO DISCUSS THE EARNINGS RESULTS IS SCHEDULED FOR THE SAME DAY AT 10:00 A.M. EASTERN TIME.

LITHIA & DRIVEWAY (LAD) SCHEDULES RELEASE OF FIRST QUARTER 2026 RESULTS

CRANBURY, N.J.--(BUSINESS WIRE)--ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT), A FULLY INTEGRATED BIOTECHNOLOGY COMPANY ADVANCING A SUSTAINABLE PIPELINE OF GENETIC THERAPIES FOR RARE DISORDERS WITH HIGH UNMET NEED, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED ACCELERATED APPROVAL FOR KRESLADI (MARNETEGRAGENE AUTOTEMCEL), AN AUTOLOGOUS HEMATOPOIETIC STEM CELL-BASED GENE THERAPY INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH SEVERE LEUKOCYTE ADHESION DEFICI.

ROCKET PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF KRESLADI FOR PEDIATRIC PATIENTS WITH SEVERE LEUKOCYTE ADHESION DEFICIENCY-I (LAD-I)

MEDFORD, ORE., MARCH 10, 2026 (GLOBE NEWSWIRE) -- LITHIA & DRIVEWAY (NYSE: LAD) TODAY ANNOUNCED A DONATION OF OVER $500,000 TO AUTOMOTIVE PROGRAMS NATIONWIDE AS PART OF THEIR HELPING DRIVE THE FUTURE INITIATIVE. THROUGH THE DONATION, 11 COLLEGES AND UNIVERSITIES WILL EACH RECEIVE $50,000 TO HELP STUDENTS ACHIEVE SUCCESS IN THEIR PROGRAMS, WITH FUNDS SUPPORTING NEW EQUIPMENT, TECHNOLOGY, AND OTHER CURRICULUM NEEDS.

Lithia Motors, Inc.

LAD

Price

Financial Reports

No items found.

Press Releases

Lithia Motors, Inc.

LAD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LAD